CLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDY AB Science SA (Euronext - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results